Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma

ALK-positive Anaplastic Large Cell Lymphoma (ALCL) represents a subset of Non-Hodgkin Lymphoma whose treatment benefited from crizotinib development, a dual ALK/MET inhibitor. Crizotinib blocks ALK-triggered pathways such as PI3K/AKT/mTOR, indispensable for survival of ALK-driven tumors. Despite the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Redaelli, Sara, Ceccon, Monica, Antolini, Laura, Rigolio, Roberta, Pirola, Alessandra, Peronaci, Marco, Gambacorti-Passerini, Carlo, Mologni, Luca
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5341951/
https://ncbi.nlm.nih.gov/pubmed/27662658
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12128
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados